Dr Arno M Wiersema (Dijklander Hospital & Amsterdam UMC, NL) discusses First results of the ACTION trial - ACT-guided heparinisation during non-cardiac arterial interventions.
1.Why was the ACTION trial needed and what does it address?
2.What is the design of the trial and study endpoints?
3.What are your findings to date and what conclusions (if any) can be made?
4.What further data should be anticipated from the trial?
Interviewer: Jonathan McKenna
Videographer: Mike Knight